Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable lung condition defined by persistent respiratory symptoms and airflow limitation that is usually progressive and not fully reversible. It arises from chronic inflammation of the airways and lung tissue, most often in response to inhaled noxious particles and gases such as tobacco smoke, and it encompasses the overlapping pathologies historically called chronic bronchitis and emphysema.

Definition

COPD is a heterogeneous lung condition characterised by chronic respiratory symptoms (dyspnoea, cough, sputum production) due to abnormalities of the airways and/or alveoli that cause persistent, often progressive airflow obstruction, defined physiologically by a post-bronchodilator FEV1/FVC ratio below 0.70 or below the lower limit of normal.

Scope

This entry covers the definition of COPD, its pathophysiology of airflow limitation and lung-tissue destruction, the role of spirometry in confirming persistent obstruction, the principal risk factors, and how exacerbations shape its course. It frames COPD as a clinical and methodological topic; it does not provide dosing, individualized diagnosis, or treatment recommendations.

Key concepts

• Persistent (largely fixed) airflow limitation
• Post-bronchodilator FEV1/FVC < 0.70
• Emphysema (alveolar destruction) and chronic bronchitis
• Small-airway disease
• Cigarette smoke and inhaled noxious exposures
• Acute exacerbations
• Alpha-1 antitrypsin deficiency
• Air trapping and hyperinflation

Mechanisms

Chronic exposure to inhaled irritants — predominantly tobacco smoke, but also biomass-fuel smoke and occupational dusts — provokes an amplified inflammatory response in susceptible individuals. This inflammation drives small-airway narrowing and fibrosis and, through a protease–antiprotease imbalance and oxidative injury, destruction of alveolar walls (emphysema) with loss of elastic recoil. Together these reduce expiratory airflow and promote air trapping and hyperinflation, producing the breathlessness and exercise limitation that characterise the disease. The genetic disorder alpha-1 antitrypsin deficiency is a recognised inherited cause that illustrates the protease–antiprotease mechanism. Recent accounts emphasise that lifelong lung-function trajectories — including impaired lung growth in early life — contribute to who develops COPD, not only the rate of later decline.

Clinical relevance

COPD is a leading cause of chronic respiratory morbidity and disability, and understanding its definition and natural history underlies how the literature appraises respiratory outcomes and interventions. This entry serves as a reference for what COPD is and how it is conceptualised; it is descriptive and is not a basis for individual diagnosis or treatment decisions.

Epidemiology

COPD affects hundreds of millions of people worldwide and is among the leading causes of death globally. Its prevalence rises with age and cumulative exposure to smoking and other inhaled risks, and the burden is shifting toward low- and middle-income settings; the Lancet Commission frames much of this burden as preventable through reduced exposure and earlier recognition.

History

The conditions now unified as COPD — chronic bronchitis and emphysema — were described separately before twentieth-century physiology linked them through the common endpoint of fixed airflow obstruction measurable by spirometry. The epidemiological identification of cigarette smoking as the dominant cause, and the later articulation of standardised diagnostic and management strategies through international initiatives such as GOLD, consolidated COPD as a defined clinical entity.

Debates

How should airflow obstruction be defined diagnostically?

A fixed post-bronchodilator FEV1/FVC threshold of 0.70 is simple and widely used but can over-diagnose obstruction in older adults and under-diagnose it in younger ones; using the statistically derived lower limit of normal is proposed as more accurate, and the choice remains debated.

Is COPD best understood as accelerated decline or lifelong trajectory?

The traditional model attributed COPD to an accelerated loss of lung function in adulthood, but evidence that reduced peak lung function attained in early life can lead to COPD without unusually fast decline has reframed it as a disorder of lifelong lung-function trajectories.

Seminal works

• vogelmeier-2017
• agusti-2019
• stolz-2022

Frequently asked questions

Is COPD the same as emphysema or chronic bronchitis?

COPD is the umbrella condition defined by persistent airflow obstruction; emphysema (destruction of alveoli) and chronic bronchitis (chronic cough with sputum) are overlapping pathological and clinical patterns that commonly coexist within it.

Why is the airflow limitation in COPD described as not fully reversible?

Unlike the variable, often reversible obstruction of asthma, the obstruction in COPD persists after bronchodilator administration because it reflects structural changes such as small-airway fibrosis and emphysematous loss of elastic recoil.